A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr mice

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 527-538

  Leng, Lin ^a   Chen, Liang ^a   Fan, Juan ^a   Greven, Dorothee ^a   Arjona, Alvaro ^a   Du, Xin ^a   Austin, David ^b   Kashgarian, Michael ^a   Yin, Zhinan ^a,e   Huang, Xiao R ^c   Lan, Hui Y ^c   Lolis, Elias ^a   Nikolic Paterson, David ^d   Bucala, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d MONASH UNIVERSITY   (Australia)

^e NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; AUTOANTIBODY; CD74 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 16; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME ACTIVE SITE; EPITOPE MAPPING; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LEUKOCYTE MIGRATION; MACROPHAGE MIGRATION INHIBITION; MOLECULAR DYNAMICS; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RENAL PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

AMINO ACID SEQUENCE; ANIMALS; CELL MIGRATION INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED MRL LPR; MICE, INBRED NZB; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RANDOM ALLOCATION; RECEPTORS, IMMUNOLOGIC;

EID: 79251539843     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001767     Document Type: Article

References (66)

1. Rahman, A., and D. A. Isenberg. 2008. Systemic lupus erythematosus. N. Engl. J. Med. 358: 929-939.
2. Peterson, K. S., and R. Winchester. 2005. Systemic lupus erythematosus: pathogenesis. In Arthritis and Allied Conditions. W. J. Koopman, and L. W. Moreland, eds. Lippincott Williams & Wilkins, Philadelphia, p. 1523-1574.
3. Calandra, T., and T. Roger. 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3: 791-800.
4. Bernhagen, J., R. Krohn, H. Lue, J. L. Gregory, A. Zernecke, R. R. Koenen, M. Dewor, I. Georgiev, A. Schober, L. Leng, et al. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13: 587-596.
5. Calandra, T., J. Bernhagen, R. A. Mitchell, and R. Bucala. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179: 1895-1902.
6. Bacher, M., C. N. Metz, T. Calandra, K. Mayer, J. Chesney, M. Lohoff, D. Gemsa, T. Donnelly, and R. Bucala. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA 93: 7849-7854.
7. Mitchell, R. A., C. N. Metz, T. Peng, and R. Bucala. 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274: 18100-18106.
8. Onodera, S., K. Kaneda, Y. Mizue, Y. Koyama, M. Fujinaga, and J. Nishihira. 2000. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem. 275: 444-450.
9. Fingerle-Rowson, G., O. Petrenko, C. N. Metz, T. G. Forsthuber, R. Mitchell, R. Huss, U. Moll, W. Müller, and R. Bucala. 2003. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc. Natl. Acad. Sci. USA 100: 9354-9359.
10. Mitchell, R. A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99: 345-350.
11. Gore, Y., D. Starlets, N. Maharshak, S. Becker-Herman, U. Kaneyuki, L. Leng, R. Bucala, and I. Shachar. 2008. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J. Biol. Chem. 283: 2784-2792.
12. Sapoznikov, A., Y. Pewzner-Jung, V. Kalchenko, R. Krauthgamer, I. Shachar, and S. Jung. 2008. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat. Immunol. 9: 388-395.
13. Leng, L., C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, and R. Bucala. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476.
14. Schwartz, V., H. Lue, S. Kraemer, J. Korbiel, R. Krohn, K. Ohl, R. Bucala, C. Weber, and J. Bernhagen. 2009. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett. 583: 2749-2757.
15. Mikulowska, A., C. N. Metz, R. Bucala, and R. Holmdahl. 1997. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J. Immunol. 158: 5514-5517.
16. de Jong, Y. P., A. C. Abadia-Molina, A. R. Satoskar, K. Clarke, S. T. Rietdijk, W. A. Faubion, E. Mizoguchi, C. N. Metz, M. Alsahli, T. ten Hove, et al. 2001. Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol. 2: 1061-1066.
17. Denkinger, C. M., M. Denkinger, J. J. Kort, C. Metz, and T. G. Forsthuber. 2003. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol. 170: 1274-1282.
18. Hoi, A. Y., M. J. Hickey, P. Hall, J. Yamana, K. M. O'Sullivan, L. L. Santos, W. G. James, A. R. Kitching, and E. F. Morand. 2006. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J. Immunol. 177: 5687-5696.
19. Baugh, J. A., S. Chitnis, S. C. Donnelly, J. Monteiro, X. Lin, B. J. Plant, F. Wolfe, P. K. Gregersen, and R. Bucala. 2002. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3: 170-176.
20. Radstake, T. R. D. J., F. C. G. J. Sweep, P. Welsing, B. Franke, S. H. H. M. Vermeulen, A. Geurts-Moespot, T. Calandra, R. Donn, and P. L. C. M. van Riel. 2005. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 52: 3020-3029.
21. Mizue, Y., S. Ghani, L. Leng, C. McDonald, P. Kong, J. Baugh, S. J. Lane, J. Craft, J. Nishihira, S. C. Donnelly, et al. 2005. Role for macrophage migration inhibitory factor in asthma. Proc. Natl. Acad. Sci. USA 102: 14410-14415.
22. Wu, S.-P., L. Leng, Z. Feng, N. Liu, H. Zhao, C. McDonald, A. Lee, F. C. Arnett, P. K. Gregersen, M. D. Mayes, and R. Bucala. 2006. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 54: 3661-3669.
23. Sánchez, E., L. M. Gómez, M. A. Lopez-Nevot, M. A. González-Gay, J. M. Sabio, N. Ortego-Centeno, E. de Ramón, J. M. Anaya, M. F. González-Escribano, B. P. Koeleman, and J. Martín. 2006. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun. 7: 433-436. (Pubitemid 44111648)
24. Foote, A., E. M. Briganti, Y. Kipen, L. Santos, M. Leech, and E. F. Morand. 2004. Macrophage migration inhibitory factor in systemic lupus erythematosus. J. Rheumatol. 31: 268-273.
25. Suzuki, M., H. Sugimoto, A. Nakagawa, I. Tanaka, J. Nishihira, and M. Sakai. 1996. Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat. Struct. Biol. 3: 259-266.
26. Rosengren, E., R. Bucala, P. Aman, L. Jacobsson, G. Odh, C. N. Metz, and H. Rorsman. 1996. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2: 143-149.
27. Fingerle-Rowson, G., D. R. Kaleswarapu, C. Schlander, N. Kabgani, T. Brocks, N. Reinart, R. Busch, A. Schütz, H. Q. Lue, X. Du, et al. 2009. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol. Cell. Biol. 29: 1922-1932.
28. Senter, P. D., Y. Al-Abed, C. N. Metz, F. Benigni, R. A. Mitchell, J. Chesney, J. Han, C. G. Gartner, S. D. Nelson, G. J. Todaro, and R. Bucala. 2002. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. USA 99: 144-149.
29. Cournia, Z., L. Leng, S. Gandavadi, X. Du, R. Bucala, and W. L. Jorgensen. 2009. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J. Med. Chem. 52: 416-424.
30. Schröder, J. O., and R. A. Zeuner. 2009. Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges. Curr. Drug Discov. Technol. 6: 252-255.
31. Lubetsky, J. B., A. Dios, J. Han, B. Aljabari, B. Ruzsicska, R. Mitchell, E. Lolis, and Y. Al-Abed. 2002. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277: 24976-24982.
32. Lubetsky, J. B., M. Swope, C. Dealwis, P. Blake, and E. Lolis. 1999. Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry 38: 7346-7354.
33. Lan, H. Y., M. Bacher, N. Yang, W. Mu, D. J. Nikolic-Paterson, C. Metz, A. Meinhardt, R. Bucala, and R. C. Atkins. 1997. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J. Exp. Med. 185: 1455-1465.
34. Bernhagen, J., R. A. Mitchell, T. Calandra, W. Voelter, A. Cerami, and R. Bucala. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144-14155. (Pubitemid 24382359)
35. Schwab, C., A. Twardek, T. P. Lo, G. D. Brayer, and H. R. Bosshard. 1993. Mapping antibody binding sites on cytochrome c with synthetic peptides: are results representative of the antigenic structure of proteins? Protein Sci. 2: 175-182.
36. Yin, Z. N., G. Bahtiyar, N. Zhang, L. Z. Liu, P. Zhu, M. E. Robert, J. McNiff, M. P. Madaio, and J. Craft. 2002. IL-10 regulates murine lupus. J. Immunol. 169: 2148-2155.
37. Austin, H. A., III, L. R. Muenz, K. M. Joyce, T. T. Antonovych, and J. E. Balow. 1984. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25: 689-695.
38. Kinoshita, K., G. Tesch, A. Schwarting, R. Maron, A. H. Sharpe, and V. R. Kelley. 2000. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J. Immunol. 164: 6046-6056.
39. Bacher, M., A. Meinhardt, H. Y. Lan, W. Mu, C. N. Metz, J. A. Chesney, T. Calandra, D. Gemsa, T. Donnelly, R. C. Atkins, and R. Bucala. 1997. Migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 150: 235-246.
40. Vera, P. L., X. H. Wang, and K. L. Meyer-Siegler. 2008. Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation. Exp. Biol. Med. (Maywood) 233: 620-626.
41. Tögel, F., J. Isaac, Z. M. Hu, K. Weiss, and C. Westenfelder. 2005. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int. 67: 1772-1784.
42. Arjona, A., H. G. Foellmer, T. Town, L. Leng, C. McDonald, T. Wang, S. J. Wong, R. R. Montgomery, E. Fikrig, and R. Bucala. 2007. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest. 117: 3059-3066.
43. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57: 289-300.
44. Crofford, L. J., and R. L. Wilder. 2001. Arthritis and autoimmunity in animals. In Arthritis and Allied Conditions. W. J. Koopman, ed. Lippincott Williams & Wilkins, Philadelphia, p. 607-634.
45. Lan, H. Y., W. Mu, N. Yang, A. Meinhardt, D. J. Nikolic-Paterson, Y. Y. Ng, M. Bacher, R. C. Atkins, and R. Bucala. 1996. De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am. J. Pathol. 149: 1119-1127.
46. Samuelsson, A., T. L. Towers, and J. V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
47. Basta, M., F. Van Goor, S. Luccioli, E. M. Billings, A. O. Vortmeyer, L. Baranyi, J. Szebeni, C. R. Alving, M. C. Carroll, I. Berkower, et al. 2003. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 9: 431-438.
48. Swant, J. D., B. E. Rendon, M. Symons, and R. A. Mitchell. 2005. Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J. Biol. Chem. 280: 23066-23072.
49. Shi, X., L. Leng, T. Wang, W. Wang, X. Du, J. Li, C. McDonald, Z. Chen, J. W. Murphy, E. Lolis, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
50. Lue, H. Q., A. Kapurniotu, G. Fingerle-Rowson, T. Roger, L. Leng, M. Thiele, T. Calandra, R. Bucala, and J. Bernhagen. 2006. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell. Signal. 18: 688-703.
51. Hudson, J. D., M. A. Shoaibi, R. Maestro, A. Carnero, G. J. Hannon, and D. H. Beach. 1999. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190: 1375-1382.
52. Fingerle-Rowson, G., and O. Petrenko. 2007. MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div. 2: 22.
53. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189: 341-346.
54. Stojanovic, I., D. Maksimovic-Ivanic, Y. Al Abed, F. Nicoletti, and S. Stosic-Grujicic. 2008. Control of the of the final stage of immune-mediated diabetes by Iso-1, an antagonist of macrophage migration inhibitory factor. Arch. Biol. Sci. 60: 389-401.
55. Xue, C. B., J. Wityak, T. M. Sielecki, D. J. Pinto, D. G. Batt, G. A. Cain, M. Sworin, A. L. Rockwell, J. J. Roderick, S. G. Wang, et al. 1997. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists. J. Med. Chem. 40: 2064-2084.
56. Al-Abed, Y., D. Dabideen, B. Aljabari, A. Valster, D. Messmer, M. Ochani, M. Tanovic, K. Ochani, M. Bacher, F. Nicoletti, et al. 2005. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280: 36541-36544.
57. Merk, M., J. Baugh, S. Zierow, L. Leng, U. Pal, S. J. Lee, A. D. Ebert, Y. Mizue, J. O. Trent, R. Mitchell, et al. 2009. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J. Immunol. 182: 6896-6906.
58. Sabzevari, H., S. Propp, D. H. Kono, and A. N. Theofilopoulos. 1997. G1 arrest and high expression of cyclin kinase and apoptosis inhibitors in accumulated activated/memory phenotype CD4+ cells of older lupus mice. Eur. J. Immunol. 27: 1901-1910.
59. Boswell, J. M., M. A. Yui, D. W. Burt, and V. E. Kelley. 1988. Increased tumor necrosis factor and IL-1 b gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 141: 3050-3054.
60. Tesch, G. H., S. Maifert, A. Schwarting, B. J. Rollins, and V. R. Kelley. 1999. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med. 190: 1813-1824.
61. Randolph, G. J., and M. B. Furie. 1995. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J. Immunol. 155: 3610-3618.
62. Pérez de Lema, G., H. Maier, T. J. Franz, M. Escribese, S. Chilla, S. Segerer, N. Camarasa, H. Schmid, B. Banas, S. Kalaydjiev, et al. 2005. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J. Am. Soc. Nephrol. 16: 3592-3601.
63. Wang, A., A. M. Fairhurst, K. Tus, S. Subramanian, Y. Liu, F. M. Lin, P. Igarashi, X. J. Zhou, F. Batteux, D. Wong, et al. 2009. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J. Immunol. 182: 4448-4458.
64. Salmon, J. E., and M. J. Roman. 2008. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am. J. Med. 121: 3-8.
65. Verschuren, L., T. Kooistra, J. Bernhagen, P. J. Voshol, D. M. Ouwens, M. van Erk, J. de Vries-van der Weij, L. Leng, J. H. van Bockel, K. W. van Dijk, et al. 2009. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ. Res. 105: 99-107.
66. Sreih, A. G., R. Ezzeddine, L. Leng, A. LaChance, G. Yu, E. Svenungsson, I. Gunnarsson, Y. Mizue, J. Cavett, S. Glenn, et al. 2009. Dual effect of MIF gene polymorphisms on the development and the severity of SLE. Arthritis Rheum. 60(Suppl. 60):119.